Does the media prefer WVE or DNLI?

In the previous week, Denali Therapeutics had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Denali Therapeutics and 2 mentions for WAVE Life Sciences. Denali Therapeutics' average media sentiment score of 1.32 beat WAVE Life Sciences' score of -0.97 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Denali Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VKTX or WVE?

In the previous week, Viking Therapeutics had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Viking Therapeutics and 2 mentions for WAVE Life Sciences. Viking Therapeutics' average media sentiment score of 1.08 beat WAVE Life Sciences' score of -0.97 indicating that Viking Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viking Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media favor LEGN or WVE?

In the previous week, Legend Biotech had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Legend Biotech and 2 mentions for WAVE Life Sciences. Legend Biotech's average media sentiment score of -0.14 beat WAVE Life Sciences' score of -0.97 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media prefer WVE or RCUS?

In the previous week, Arcus Biosciences had 4 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for Arcus Biosciences and 2 mentions for WAVE Life Sciences. Arcus Biosciences' average media sentiment score of 0.71 beat WAVE Life Sciences' score of -0.97 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer GMTX or WVE?

WAVE Life Sciences has a consensus price target of $22.53, suggesting a potential upside of 325.89%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 WAVE Life Sciences 1 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.81

Does the media refer more to GMTX or WVE?

In the previous week, WAVE Life Sciences had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for WAVE Life Sciences and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat WAVE Life Sciences' score of -0.97 indicating that Gemini Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

WAVE Life Sciences (WVE) Competitors

$5.29 +0.04 (+0.76%)

As of 08/21/2026 04:00 PM Eastern

Compare

WVE vs. DNLI, VKTX, LEGN, RCUS, and GMTX

Should you buy WAVE Life Sciences stock or one of its competitors? WAVE Life Sciences's main competitors and comparable companies include Denali Therapeutics (DNLI), Viking Therapeutics (VKTX), Legend Biotech (LEGN), Arcus Biosciences (RCUS), and Gemini Therapeutics (GMTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does WAVE Life Sciences compare to Denali Therapeutics?

WAVE Life Sciences (NASDAQ:WVE) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

WAVE Life Sciences has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A
Denali Therapeutics	$330.53M	12.05	-$512.54M	-$2.84	N/A

WAVE Life Sciences currently has a consensus target price of $22.53, suggesting a potential upside of 325.89%. Denali Therapeutics has a consensus target price of $35.92, suggesting a potential upside of 44.13%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe WAVE Life Sciences is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Denali Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Denali Therapeutics	N/A	-55.27%	-44.24%

WAVE Life Sciences has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Denali Therapeutics had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Denali Therapeutics and 2 mentions for WAVE Life Sciences. Denali Therapeutics' average media sentiment score of 1.32 beat WAVE Life Sciences' score of -0.97 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Denali Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats Denali Therapeutics on 10 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Viking Therapeutics currently has a consensus price target of $96.63, suggesting a potential upside of 185.11%. WAVE Life Sciences has a consensus price target of $22.53, suggesting a potential upside of 325.89%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than Viking Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, meaning that its share price is 226% less volatile than the broader market.

Viking Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-94.56%	-82.75%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, Viking Therapeutics had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Viking Therapeutics and 2 mentions for WAVE Life Sciences. Viking Therapeutics' average media sentiment score of 1.08 beat WAVE Life Sciences' score of -0.97 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viking Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

WAVE Life Sciences has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.66	N/A
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A

Summary

WAVE Life Sciences beats Viking Therapeutics on 11 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Legend Biotech has a net margin of -7.21% compared to WAVE Life Sciences' net margin of -309.73%. Legend Biotech's return on equity of -8.71% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-7.21%	-8.71%	-5.40%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

WAVE Life Sciences has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	3.94	-$296.80M	-$0.25	N/A
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A

In the previous week, Legend Biotech had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 5 mentions for Legend Biotech and 2 mentions for WAVE Life Sciences. Legend Biotech's average media sentiment score of -0.14 beat WAVE Life Sciences' score of -0.97 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Legend Biotech currently has a consensus target price of $52.29, suggesting a potential upside of 139.62%. WAVE Life Sciences has a consensus target price of $22.53, suggesting a potential upside of 325.89%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe WAVE Life Sciences is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Legend Biotech has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market.

Summary

Legend Biotech and WAVE Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Arcus Biosciences?

WAVE Life Sciences (NASDAQ:WVE) and Arcus Biosciences (NYSE:RCUS) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

WAVE Life Sciences has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A
Arcus Biosciences	$247M	15.54	-$353M	-$3.90	N/A

WAVE Life Sciences currently has a consensus target price of $22.53, indicating a potential upside of 325.89%. Arcus Biosciences has a consensus target price of $37.80, indicating a potential upside of 25.41%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe WAVE Life Sciences is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

89.7% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 24.3% of WAVE Life Sciences shares are held by insiders. Comparatively, 7.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

WAVE Life Sciences has a net margin of -309.73% compared to Arcus Biosciences' net margin of -393.16%. WAVE Life Sciences' return on equity of -50.36% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WAVE Life Sciences	-309.73%	-50.36%	-40.06%
Arcus Biosciences	-393.16%	-89.54%	-45.61%

WAVE Life Sciences has a beta of -1.26, suggesting that its stock price is 226% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

In the previous week, Arcus Biosciences had 4 more articles in the media than WAVE Life Sciences. MarketBeat recorded 6 mentions for Arcus Biosciences and 2 mentions for WAVE Life Sciences. Arcus Biosciences' average media sentiment score of 0.71 beat WAVE Life Sciences' score of -0.97 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

WAVE Life Sciences beats Arcus Biosciences on 11 of the 16 factors compared between the two stocks.

How does WAVE Life Sciences compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and WAVE Life Sciences (NASDAQ:WVE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Gemini Therapeutics has a net margin of 0.00% compared to WAVE Life Sciences' net margin of -309.73%. Gemini Therapeutics' return on equity of -38.78% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, WAVE Life Sciences had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 2 mentions for WAVE Life Sciences and 1 mentions for Gemini Therapeutics. Gemini Therapeutics' average media sentiment score of 0.75 beat WAVE Life Sciences' score of -0.97 indicating that Gemini Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

WAVE Life Sciences has a consensus price target of $22.53, suggesting a potential upside of 325.89%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

75.4% of Gemini Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 12.9% of Gemini Therapeutics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Gemini Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. Gemini Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A

Gemini Therapeutics has a beta of -0.12, indicating that its stock price is 112% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market.

Summary

WAVE Life Sciences beats Gemini Therapeutics on 8 of the 15 factors compared between the two stocks.

Get WAVE Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WVE vs. The Competition

Export

Metric	WAVE Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.04B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-4.85	11.62	272.60	24.24
Price / Sales	24.39	1,338.17	618.96	99.78
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	2.30	16.80	13.05	6.20
Net Income	-$204.38M	-$12.50M	$3.47B	$348.59M
7 Day Performance	-2.22%	3.29%	2.09%	0.08%
1 Month Performance	-8.48%	8.23%	6.64%	3.88%
1 Year Performance	-47.88%	55.05%	25.02%	16.98%

WAVE Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WVE WAVE Life Sciences	2.7798 of 5 stars	$5.29 +0.8%	$22.53 +325.9%	-47.9%	$1.04B	$42.73M	N/A	240	Analyst Downgrade
DNLI Denali Therapeutics	3.3975 of 5 stars	$24.40 -1.7%	$35.92 +47.2%	+60.9%	$3.97B	$330.53M	N/A	430	News Coverage Positive News
VKTX Viking Therapeutics	3.2335 of 5 stars	$33.19 +0.8%	$96.63 +191.1%	+30.3%	$3.84B	N/A	N/A	20	Analyst Upgrade
LEGN Legend Biotech	2.834 of 5 stars	$20.37 +0.5%	$52.29 +156.7%	-38.6%	$3.76B	$1.03B	N/A	2,965	Analyst Downgrade Analyst Revision
RCUS Arcus Biosciences	2.9992 of 5 stars	$29.50 +2.2%	$37.80 +28.2%	+186.8%	$3.67B	$247M	N/A	500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WVE) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

WAVE Life Sciences (WVE) Competitors

WVE vs. DNLI, VKTX, LEGN, RCUS, and GMTX

How does WAVE Life Sciences compare to Denali Therapeutics?

Summary

How does WAVE Life Sciences compare to Viking Therapeutics?

Summary

How does WAVE Life Sciences compare to Legend Biotech?

Summary

How does WAVE Life Sciences compare to Arcus Biosciences?

Summary

How does WAVE Life Sciences compare to Gemini Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

WAVE Life Sciences (WVE) Competitors

WVE vs. DNLI, VKTX, LEGN, RCUS, and GMTX

How does WAVE Life Sciences compare to Denali Therapeutics?

Which has preferable valuation & earnings, WVE or DNLI?

Do analysts recommend WVE or DNLI?

Is WVE or DNLI more profitable?

Which has more risk & volatility, WVE or DNLI?

Do insiders and institutionals believe in WVE or DNLI?

Does the media prefer WVE or DNLI?

Summary

How does WAVE Life Sciences compare to Viking Therapeutics?

Do insiders & institutionals hold more shares of VKTX or WVE?

Do analysts rate VKTX or WVE?

Which has more volatility and risk, VKTX or WVE?

Is VKTX or WVE more profitable?

Does the media favor VKTX or WVE?

Which has better valuation and earnings, VKTX or WVE?

Summary

How does WAVE Life Sciences compare to Legend Biotech?

Is LEGN or WVE more profitable?

Do insiders and institutionals have more ownership in LEGN or WVE?

Which has better earnings and valuation, LEGN or WVE?

Does the media favor LEGN or WVE?

Do analysts recommend LEGN or WVE?

Which has more volatility and risk, LEGN or WVE?

Summary

How does WAVE Life Sciences compare to Arcus Biosciences?

Which has better earnings and valuation, WVE or RCUS?

Do analysts recommend WVE or RCUS?

Do insiders & institutionals have more ownership in WVE or RCUS?

Is WVE or RCUS more profitable?

Which has more volatility & risk, WVE or RCUS?

Does the media prefer WVE or RCUS?

Summary

How does WAVE Life Sciences compare to Gemini Therapeutics?

Is GMTX or WVE more profitable?

Does the media refer more to GMTX or WVE?

Do analysts prefer GMTX or WVE?

Do insiders & institutionals hold more shares of GMTX or WVE?

Which has higher earnings and valuation, GMTX or WVE?

Which has more risk & volatility, GMTX or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WVE vs. The Competition

WAVE Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools